Multiple Myeloma Trials

Janssen 54767414 MMY3021 “Auriga”

A Randomized Study of Daratumumab plus Lenalidomide vs. Lenalidomide Alone vs Maintenance Treatment in Patients with Newly Diagnosed Mulitple Myeloma Who Are Minimal Residual Disease Positive after Frontline Autologous Stem Cell Transplant.

Janssen 54767414 MMY2065 “Lynx”

A Phase 2 Study Comparing Daratumumab Subcutaneous Administration in Combination with Carfilzomib, and Dexamethasone (DKd) vs Carfilzomib and Dexamethasone (Kd) in Subjects with Multiple Myeloma who have been Previously treated with Daratumumab IV.

Fort Wayne North Office
(260) 484-8830
2514 E Dupont Road, Suite 100
Fort Wayne, IN 46825

Fort Wayne South Office
(260) 436-0800
7910 West Jefferson Boulevard, Suite 108
Fort Wayne, Indiana 46804

©2019 Fort Wayne Medical Oncology and Hematology. All Rights Reserved.